February 2016

Effectively presenting critical study endpoints in an abbreviated timeframe

Monday, February 29, 2016

The Pulse on Study Conduct by Elizabeth Weeks-Rowe

A response to any message must be carefully crafted, considered and reconsidered before being sent, as we all know. One cannot reach into cyberspace and easily recall a transmission. Once the message is received, words therein are part of the proverbial audit trail critical to research documentation. This is why I hovered indecisively over my keyboard after reading a frustrating email from a co-worker that signaled an impending issue.

[Read More]

Can trials be conducted 100% via mobile app? Results say yes

Monday, February 29, 2016

The BRIGHTEN clinical trial recently brought mental health into the 21st century using mobile technology to conduct a trial from patient recruitment to final assessment, including the delivery of the treatment interventions. The trial was led by Dr. Patricia Areán, a licensed clinical psychologist and professor of Psychology and Behavioral Sciences at the University of Washington

[Read More]

Pete Nicholas to retire at Boston Scientific

Monday, February 29, 2016

Pete M. Nicholas, the company’s co-founder and chairman of its board, will retire from the board of Boston Scientific in May. Nicholas served as Boston Scientific’s chief executive officer and co-chairman of the board since its founding in 1979. In 1995, Pete stepped down as CEO and became its chairman. During his almost 40 years of leadership, the company grew to become a global leader in the field of interventional medicine, improving the lives of patients worldwide.

[Read More]

OSE Pharma, Effimune to merge

Friday, February 26, 2016

OSE Pharma, an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration phase III study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, have announce the signing of a proposed merger agreement.

[Read More]

Baxalta, Precision BioSciences ink $1.6B immuno-oncology collaboration

Friday, February 26, 2016

Baxalta, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, a genome editing company, have announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers.

[Read More]

CHOP, Seven Bridges form Cavatica for pediatric cancer genomics data

Friday, February 26, 2016

The Children’s Hospital of Philadelphia (CHOP), the lead operations center for the Childhood Brain Tumor Tissue Consortium (CBTTC), and Seven Bridges, a biomedical data analysis company, have announced the joint development of Cavatica, a new cloud-based environment for securely storing, sharing and analyzing large volumes of pediatric cancer patient genomics data. Cavatica will support CHOP’s commitment to the White House Precision Medicine Initiative (PMI) through the newly launched Center for Data Driven Discovery in Biomedicine (D3b), located at CHOP. 

[Read More]

Certara launches Phoenix Technology Services for R&D productivity

Thursday, February 25, 2016

Certara, a global biosimulation technology-enabled drug development company, today announced the introduction of Phoenix Technology Services. These services, led and implemented by Certara’s team of biosimulation (modeling and simulation) experts, include customized and ready-to-use solutions that span the breadth of the Phoenix platform.

[Read More]

Exco InTouch focuses on Valued Partner Network

Thursday, February 25, 2016

Exco InTouch has expanded the company’s global reach, launching a Valued Partner Network that provides extensive support to CROs and technology service providers by integrating market leading patient engagement and electronic Clinical Outcome Assessment (eCOA) capabilities into their existing service portfolios.

[Read More]